TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05625451

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Elastic Tension Digital Neoprene Orthosis
Description: The treatment consisted of an exercise program in conjunction with the use of an extension elastic tension digital neoprene orthosis to generate two different daily total end range time doses. Group A patients used a dose of twenty to twenty-two hours of daily total end range time while group B patients used the extension elastic tension digital neoprene orthosis to achieve a daily total end range time between eleven and thirteen hours for a mean of twenty hours a day. The exercise program was the same for both groups.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Elastic Tension Digital Neoprene Orthosis
Description: The treatment consisted of an exercise program in conjunction with the use of an extension elastic tension digital neoprene orthosis to generate two different daily total end range time doses. Group A patients used a dose of twenty to twenty-two hours of daily total end range time while group B patients used the extension elastic tension digital neoprene orthosis to achieve a daily total end range time between eleven and thirteen hours for a mean of twenty hours a day. The exercise program was the same for both groups.
Study: NCT00720772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25% intravenous (IV) sodium thiosulfate
Description: 50 ml IV drip twice/week post hemodialysis
Study: NCT04266600

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extensive mesentery resection
Description: Surgeons will perform a high ligation of the ileocolic pedicle, between the superior mesenteric artery and the bifurcation of the ileal and right colic branches, and to fully mobilize the mesentery off of the retroperitoneum prior to bowel transection and anastomosis
Study: NCT04134988

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medimoov
Description: The Medimoov game platform (created by NaturalPad©) is a physio-gaming medical device, which comes in the form of functional and postural rehabilitation software. Associating movement capture and videogames, Medimoov contributes to the older adults' motivation and engagement and offers adapted physical activities.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard psychomotor therapy
Description: Psychomotor therapists are among the professionals recommended by the French national health authority. They intervene on psychomotor dimensions of falls, namely the motor, sensory and cognitive aspects.
Study: NCT01744938

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: preoperative biliary drainage
Description: percutaneous preoperative biliary drainage guided by CT
Study: NCT02083120

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NHF therapy
Description: AIRVO 2 device therapy is either a humidifier with integrated flow generator that delivers warmed and humidified respiratory gases to spontaneously breathing patients through a variety of patient interfaces. Flow rates up to 60 L/min are available to the user, depending on the patient interface and mode of operation.In this study, flow rates of 20 L/min and 35 L/min will be compared.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Long term Oxygen Therapy (LOT)
Description: Oxygen will individually be added to NHF in order to achieve stable oxygen saturation by pulse oximetry (SpO2) values of 88% to 92%.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Long term Oxygen Therapy (LOT)
Description: Oxygen will individually be added to NHF in order to achieve stable oxygen saturation by pulse oximetry (SpO2) values of 88% to 92%.
Study: NCT01373073

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental human milk fortifier
Description: Human milk fortifier to be added to human milk feedings

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control human milk fortifier
Description: Control human milk fortifier to be added to human milk
Study: NCT02775773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: 2 vials ( =1 gram) of Tranexamic Acid slow intravenous infusion administered within 5 minutes from the delivery (third stage after labor)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: 2 vials (=10 IU/International Unit) of Oxytocin administered intramuscularly within 5 minutes from the delivery (third stage after labor)
Study: NCT02289573

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NAVA and PSV
Description: change ventilation modes(NAVA and PSV) with different support levels

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: NAVA and PSV
Description: change ventilation modes(NAVA and PSV) with different support levels
Study: NCT00626626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofar, Cyclophos, Alemtuzumab
Description: Hydrocortisone 100 mg IV 30 minutes prior to each dose of Clofarabine. Ondansetron 16 mg PO or IV or another comparable antiemetic should be given prior to each dose of Clofarabine. An additional similar dose should be given prior to Cyclophosphamide dose. Clofarabine 30 mg/M2 -8 through - 4 (5 doses) infusion. Alemtuzumab on day -8 only and after Clofarabine. Cyclophosphamide 500 mg/m2 Days -8 and -7 (2 doses) given over 1 hour beginning 4 hours after the beginning of Clofarabine infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofar, Cyclophos,Alemtuzumab(Ph II)
Description: Hydrocortisone 100 mg IV 30 minutes prior to each dose of Clofarabine. Ondansetron 16 mg PO or IV or another comparable antiemetic should be given prior to each dose of Clofarabine. An additional similar dose should be given prior to Cyclophosphamide dose. Clofarabine 30 mg/M2 -8 through - 4 (5 doses) infusion. Alemtuzumab on day -8 only and after Clofarabine. Cyclophosphamide 1000 mg/m2 Days -8 and -7 (2 doses) given over 1 hour beginning 4 hours after the beginning of Clofarabine infusion (patients 4-9)
Study: NCT02393027

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: [18F] LBT-999 PET

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F] LBT-999 PET
Study: NCT03971383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aolanti Weipang Tablets
Description: 3 tablets one time, 3 times a day(tid)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 tablets one time, 3 times a day(tid)
Study: NCT01348568

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: low glycemic index diet with canola oil bread

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High fiber diet
Study: NCT03130881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLB1003
Description: PLB1003 is a capsule and is administered orally.
Study: NCT05057780

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Communication Skills Curriculum
Description: Our novel intervention adapted curricula around effective skills used to navigate common communication challenges in clinical practice. These skills were selected after determining patterns from multiple communication sessions delivered to over 6,000 healthcare providers. Our main goal was to enhance communication with patients by helping residents gain confidence and competence using these under-utilized communication skills, regardless of the communication challenge. Over the course of three, 1-hour long sessions on communication in the 2017-2018 academic year, internal medicine residents learned three of these highly effective and often under-utilized skills; reflective listening, responding to emotion and reframing, respectively.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Communication Skills Curriculum
Description: Our novel intervention adapted curricula around effective skills used to navigate common communication challenges in clinical practice. These skills were selected after determining patterns from multiple communication sessions delivered to over 6,000 healthcare providers. Our main goal was to enhance communication with patients by helping residents gain confidence and competence using these under-utilized communication skills, regardless of the communication challenge. Over the course of three, 1-hour long sessions on communication in the 2017-2018 academic year, internal medicine residents learned three of these highly effective and often under-utilized skills; reflective listening, responding to emotion and reframing, respectively.
Study: NCT05228743

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Comparing Hyperthermic Intraperitoneal Chemotherapy
Description: After laparoscopic exploration, HIPEC was started immediately: the temperature was 43 ℃ and the duration was 60 min. paclitaxel (PTX) was used with a dose of 50mg / m2. The second HIPEC was completed 24-48 hrs after the first HIPEC, and at least 4 HIPEC was completed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: A natural anticancer drug that has been widely used in the treatment of breast, ovarian and some head and neck and lung cancers.Three to six weeks after HIPEC was completed, chemotherapy was started:: PTX: 50mg / m2 IV, D1, D8; PTX: 20mg / m2 IP, D1, D8; q3w; S-1: 60mg / m2, bid, d1-14, repeated every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1
Description: S-1 is an oral fluoropyrimidine consisting of tegafur (a prodrug that is converted to fluorouracil, mainly in liver microsomes but also in tumour tissue), gimeracil (an inhibitor of dihydropyrimidine dehydrogenase, which degrades 5-FU), and oteracil (which inhibits the phosphorylation of 5-FU in the gastrointestinal tract, thereby reducing the toxic effects of 5-FU in the intestinum).Three to six weeks after HIPEC was completed, chemotherapy was started:: PTX: 50mg / m2 IV, D1, D8; PTX: 20mg / m2 IP, D1, D8; q3w; S-1: 60mg / m2, bid, d1-14, repeated every 3 weeks.
Study: NCT02757872

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Vitamin D3 (cholecalciferol), 2000 IU per day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Vitamin D3 (cholecalciferol), 2000 IU per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 Fatty acids
Description: Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\])

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 Fatty acids
Description: Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\])

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3 placebo
Description: Vitamin D3 placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 placebo
Description: Vitamin D3 placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fish oil placebo
Description: Fish oil placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish oil placebo
Description: Fish oil placebo
Study: NCT03693326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: PDR001 300 mg (fixed dose) intraveneously every 3 weeks
Study: NCT04399759

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Approach-Instrumental Activities of Daily Living
Description: Individualized instrumental activities of daily living training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home health education
Description: Individualized home health education
Study: NCT02065687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Administration
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT01569477

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentives for abstinence and treatment engagement
Description: Treatment incentives - incentives for biochemical verification visits, treatment engagement and abstinence

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attendance incentive
Description: Attendance Incentives - incentives for only attending the biochemical verification visits
Study: NCT01180205

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan
Description: Telmisartan (80 mg ,Tablets, QD, p.o., 26 weeks)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Amlodpine 5 mg po 14 days, the forced - titration to 10 mg po for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olmesartan medoxomil
Description: Olmesartan 40 mg po for 26 weeks
Study: NCT03860636

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test for estradiol at ET
Description: Blood test
Study: NCT01180205

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: HCT 12,5 mg po for 14 days, then 25 mg po for 24 weeks
Study: NCT04585867

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exparel
Description: The injections will be performed under direct guidance by the cardiac surgeon at bilateral sternal-costal interspaces 1.5 cm lateral the sternal boarder at levels 2-6 in divided doses (2 ml/injection) just before the closure of the sternum near the end of the surgical procedure. The final 20 ml will be injected into the skin incision after closure
Study: NCT03860636

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test for estradiol at ET
Description: Blood test

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test for estradiol at coordination scan
Description: Blood test

Intervention type: DIAGNOSTIC_TEST
Intervention: Endometrial blood flow (doppler) at HCG
Description: Ultrasound scan

Intervention type: DIAGNOSTIC_TEST
Intervention: Endometrial blood flow (doppler) at TVOR
Description: Ultrasound scan

Intervention type: DIAGNOSTIC_TEST
Intervention: Endometrial blood flow (doppler) at ET
Description: Ultrasound scan

Intervention type: DIAGNOSTIC_TEST
Intervention: Endometrial blood flow (doppler) at ET
Description: Ultrasound scan

Intervention type: DIAGNOSTIC_TEST
Intervention: Endometrial blood flow (doppler) at coordination scan
Description: Ultrasound scan

Intervention type: DIAGNOSTIC_TEST
Intervention: Contractility at embryo transfer on a subgroup of participants
Description: Ultrasound scan
Study: NCT04585867

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: The injections will be performed under direct guidance by the cardiac surgeon at bilateral sternal-costal interspaces 1.5 cm lateral the sternal boarder at levels 2-6 in divided doses (2 ml/injection) just before the closure of the sternum near the end of the surgical procedure. The final 20 ml will be injected into the skin incision after closure
Study: NCT04560010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid Injection (TXA)
Description: Injection of 1 gram of IV TXA before surgical plus 1 gram of IV TXA three hours later
Study: NCT03746782

Intervention type: DIAGNOSTIC_TEST
Intervention: Flow Cytrometry; Thrombin Generation Assay
Description: Apixaban combined with blood specimens (in vitro) of study participants

Intervention type: DIAGNOSTIC_TEST
Intervention: Flow Cytrometry; Thrombin Generation Assay
Description: Apixaban combined with blood specimens (in vitro) of study participants

Intervention type: DIAGNOSTIC_TEST
Intervention: Flow Cytrometry; Thrombin Generation Assay
Description: Apixaban combined with blood specimens (in vitro) of study participants
Study: NCT03860636

Intervention type: DIAGNOSTIC_TEST
Intervention: Contractility at embryo transfer on a subgroup of participants
Description: Ultrasound scan

Intervention type: DIAGNOSTIC_TEST
Intervention: Change in endometrial pattern between coordination scan and ET
Description: Ultrasound scan

Intervention type: DIAGNOSTIC_TEST
Intervention: Change in endometrial pattern between HCG and ET
Description: Ultrasound scan
Study: NCT03838120

Intervention type: OTHER
Group type: OTHER
Intervention: Procedure/Surgery: bupivakain % 0,5
Description: In this study, 5 patients were included in each volume group and at least 3 applications out of 5 had to be successful to consider the volume to be sufficient. After a successful group, the volume was reduced by 2 ml's and the same procedure was followed until a final group with unsuccessful anesthesia was found (≤2 successful blockades). The study was ended at this point and MEV was determined as the volume used in the last successful group. The researcher which determined the success of blockade was blinded to the study protocol. BMI, ASA Score, Successful blockade onset time Regression time of sensorial blockade Regression time of motor blockade Time of first additional analgesic requirement
Study: NCT00564889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 300 mg/m\^2 days 1, 8 \& 15 of a 28 day cycle taken orally with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: 40 mg weekly taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: 15 mg daily days 1-21 of a 28 day cycle taken orally with food
Study: NCT04996732

Intervention type: PROCEDURE
Intervention: hospitalization
Description: Including various treatments such as surgery, radiotherapy, chemotherapy and immunotherapy during hospitalization
Study: NCT02342470

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug : Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PMK-S005 1
Description: Drug : PMK-S005 1 (50mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PMK-S005 2
Description: Drug : PMK-S005 2 (100mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PMK-S005 3
Description: Drug : PMK-S005 3 (150mg)
Study: NCT04611308

Intervention type: OTHER
Intervention: C1q tumor necrosis factor-related protein 6 levels
Description: C1q tumor necrosis factor-related protein 6 is a tumor marker

Intervention type: OTHER
Intervention: C1q tumor necrosis factor-related protein 6 levels
Description: C1q tumor necrosis factor-related protein 6 is a tumor marker
Study: NCT02138708

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological test of pulmonary endothelial
Study: NCT01542827

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biofreeze
Description: The gel will be applied at 2.5 ml per 500 cm2 to the upper trapezius and neck muscles by a gloved technician

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The gel will be applied at 2.5 ml per 500 cm2 to the upper trapezius and neck muscles by a gloved technician
Study: NCT03393182

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TLDG arm
Description: After lymphadenectomy, gastrectomy and reconstruction procedure are performed intracorporeally without mini-laparotomy(TLDG)
Study: NCT02081417

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Seeking Safety
Description: SS is a present-focused clinical intervention designed to target trauma/PTSD and SUDs.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Seeking Safety
Description: SS is a present-focused clinical intervention designed to target trauma/PTSD and SUDs.
Study: NCT02644291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mebendazole
Description: chewable mebendazole tablets that can also be crushed and mixed with food or drink to be taken daily with meals
Study: NCT03393182

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LADG arm
Description: After lymphadenectomy, gastrectomy and reconstruction procedure are performed extracorporeally through mini-laparotomy(LADG)
Study: NCT00617279

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GORE PROPATEN Vascular Graft
Description: Arterial Occlusion Bypass
Study: NCT02722642

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bronchial basal cells
Description: Patients will receive 10\^6 (1 million) /Kg/person cells of clinical grade bronchial basal cells (BBCs) injected via fiberoptic bronchoscopy after fully lavage of the localized lesions.
Study: NCT01141647

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vocational Rehabilitation
Description: SCI-VIP: PrOMOTE evidence-based supported employment implemented for Veterans with spinal cord injury or other available vocational services
Study: NCT00393783

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MAB HER 2 (HERCEPTIN)
Description: Rat HER2 DNA will be delivered intramuscularly at four different dose levels (0.5mg, 1mg, 3mg, or 6mg) during weeks 1, 4, 7, 10 and 13 for five injections.
Study: NCT02974439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LANDI-Amlodipine Besylate Tablet 5mg
Description: LANDI-Amlodipine Besylate Tablet 5mg is a generic product manufactured by YangTZE River Pharmaceutical Group Shanghai Haini Pharmaceutical Co., Ltd.
Study: NCT00617279

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Disadvantaged Autologous Vein Graft
Description: Arterial Occlusion Bypass
Study: NCT01916200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine CR
Description: Paroxetine CR will be provided by GlaxoSmithKline (GSK) and be available as 12.5 mg over-encapsulated tablets with the research use only label outside the package. Paroxetine CR should be administered as a single daily dose, with or without food. The recommended initial dose is 25 mg/day. Patients were dosed in a range of 25 mg to 62.5 mg/day in the clinical trials demonstrating the effectiveness of paroxetine CR in the treatment of major depressive disorder. As with all drugs effective in the treatment of major depressive disorder, the full effect may be delayed. Some patients not responding to a 25-mg dose may benefit from dose increases, in 12.5 mg/day increments, up to a maximum of 62.5 mg/day. Dose changes should occur at intervals of at least 1 week.